公开(公告)号：US20200179339A1

公开(公告)日：2020-06-11

申请号：US16704447

申请日：2019-12-05

申请人： CADILA HEALTHCARE LIMITED

发明人： Mukul R. JAIN ,  Abhijit CHATTERJEE ,  Kaushik BANERJEE ,  Jaideep SINGH ,  Sunita SINGH ,  Jitendrakumar PATEL

IPC分类号： A61K31/4015 ,  A61K31/4025 ,  A61K31/196 ,  A61K9/06 ,  A61K47/38 ,  A61K47/10 ,  A61K47/18 ,  A61K47/22 ,  A61K47/12 ,  A61P17/00

摘要： The present invention provides a combination of PDE4 inhibitors or pharmaceutically acceptable salts thereof along with at least one secondary therapeutic agent. The present invention also provides process for the preparation of topical pharmaceutical composition of said combination with one or more pharmaceutically acceptable excipients. The present invention further relates to use of topical pharmaceutical composition for the treatment of atopic dermatitis.

公开(公告)号：US20160068484A1

公开(公告)日：2016-03-10

申请号：US14783336

申请日：2014-07-04

申请人： CADILA HEALTHCARE LIMITED

发明人： Mukul R. JAIN ,  Suresh GIRI ,  Himanshu M. KOTHARI ,  Kaushik BANERJEE ,  Rashmikant KACHHIYA

IPC分类号： C07D207/333 ,  A61K45/06 ,  C07C211/27 ,  C07C279/14 ,  C07C215/10 ,  C07C229/26 ,  C07D295/027 ,  C07D233/58 ,  C07C215/12 ,  C07C215/40 ,  C07C211/35 ,  C07C211/30 ,  C07C217/60 ,  C07C211/51 ,  C07C211/11 ,  A61K31/4985 ,  A61K31/155 ,  A61K31/505 ,  A61K38/26 ,  A61K31/4015 ,  A61K31/40

CPC分类号： C07D207/333 ,  A61K31/155 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/4985 ,  A61K31/505 ,  A61K31/64 ,  A61K38/26 ,  A61K45/06 ,  A61K2300/00 ,  C07C211/11 ,  C07C211/27 ,  C07C211/30 ,  C07C211/35 ,  C07C211/51 ,  C07C215/10 ,  C07C215/12 ,  C07C215/40 ,  C07C217/60 ,  C07C229/26 ,  C07C279/14 ,  C07C2601/14 ,  C07D233/58 ,  C07D295/027

摘要： The present invention describes a synergistic composition comprising of one or more statins, or one or more dipeptidyl peptidase IV (DPP IV) inhibitor or one or more biguanide antihyperglycaemic agent and a PPAR agonist of formula (Ia) for the treatment of diabetes, especially non-insulin dependent diabetes (NIDDM) or Type 2 diabetes and conditions associated with diabetes mellitus and to compositions suitable for use in such method. The invention also describes the preparation of such compositions. The present invention also relates to certain novel salts of the PPAR agonist of formula (I): processes for the preparation of these novel salts and use thereof.

摘要翻译： 本发明描述了一种协同组合物，其包含一种或多种他汀类或一种或多种二肽基肽酶IV（DPP IV）抑制剂或一种或多种双胍抗高血糖药和式（Ia）的PPAR激动剂，用于治疗糖尿病， - 胰岛素依赖性糖尿病（NIDDM）或2型糖尿病和与糖尿病有关的病症以及适用于该方法的组合物。 本发明还描述了这种组合物的制备。 本发明还涉及式（I）的PPAR激动剂的某些新型盐：这些新型盐的制备方法及其用途。

公开(公告)号：US20220289846A1

公开(公告)日：2022-09-15

申请号：US17625551

申请日：2020-07-09

申请人： CADILA HEALTHCARE LIMITED

发明人： Sanjeev Kumar MENDIRATTA ,  Kaushik BANERJEE ,  Dipti MEHTA ,  Ramkrashan KASERA ,  Arun SINGH ,  Aashini PARIKH ,  Pankaj KALITA ,  Ritu UPADHYAY ,  Vibhuti SHARMA ,  Hardik PANDYA

IPC分类号： C07K16/28 ,  A61K51/10 ,  A61K47/68 ,  C07K16/32

摘要： The present invention relates to an antibody or antigen-binding portion thereof that can bind to human programmed death 1 (PD-1). The antibody according to the present invention is further used in the preparation of a drug for treating disease in which expression of PD-1 is detrimental.

公开(公告)号：US20180311241A1

公开(公告)日：2018-11-01

申请号：US15771334

申请日：2016-10-20

申请人： CADILA HEALTHCARE LIMITED

发明人： Mukul JAIN ,  Kaushik BANERJEE ,  Amit JOHARAPURKAR ,  Arti PANDYA ,  Vishal PATEL

IPC分类号： A61K31/513

CPC分类号： A61K31/506 ,  A61K31/216 ,  A61K45/06 ,  A61K2300/00

摘要： The present invention describes a synergistic composition comprising of Fimasartan or pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof for the treatment of cardiovascular and related disease. The present invention is directed to a synergistic combination comprising combinations of Fimasartan or suitable pharmaceutically effective salts thereof and a NEP inhibitor or pharmaceutically effective salts thereof in a single unit pharmaceutical composition. The present invention is further directed to combinations of Fimasartan or a pharmaceutically effective salt thereof and a NEP inhibitor or a pharmaceutically effective salt thereof. The invention also relates to combining separate pharmaceutical compositions of Fimasartan and a NEP inhibitor in kit form. The invention is further related to methods of preparing such pharmaceutical composition in separate in either a kit form containing both the active agents and methods of treating a subject with the same.